Is antipsychotic medication stigmatizing for people with mental illness?

References

• American Diabetes Association & American Psychiatric Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–561
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (Revision). American Psychiatric Press, Washington, DC 2002
   Google Scholar
• Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin 1993; 19(3)609–618
   PubMedGoogle Scholar
• Awad AG, Voruganti LN, Keslegrave RJ, Hogan TP. Assessment of the patient's subjective experience in acute neuroleptic treatment: Implications for compliance and outcome. International Clinical Psychopharmacology 1996; 11(Suppl 2)55–59
   PubMedGoogle Scholar
• Camp DL, Finlay WM, Lyons E. Is low self-esteem an inevitable consequence of stigma? An example from women with chronic mental health problems. Social Science and Medicine 2002; 55(5)823–834
   PubMedGoogle Scholar
• Carrick R, Mitchell A, Powell RA, Lloyd K. The quest for well-being: A qualitative study of the experience of taking antipsychotic medication. Psychology and Psychotherapy: Theory, Research and Practice 2004; 77: 19–33
   PubMedGoogle Scholar
• Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harvard Review of Psychiatry 2005; 13(1)28–42
   PubMed Web of Science ®Google Scholar
• Davidhizar RE. Can clients with schizophrenia describe feelings and beliefs about taking medication?. Journal of Advanced Nursing 1985; 10: 469–473
   PubMedGoogle Scholar
• Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatient s toward psychiatric medications: Relationship to clinical variables and insight. Journal of Clinical Psychiatry 2004; 65(10)1372–1376
   PubMedGoogle Scholar
• Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: International survey and comparison. British Journal of Psychiatry 2005; 187: 248–255
   PubMed Web of Science ®Google Scholar
• Ghaemi SN. New treatments for bipolar disorder: The role of atypical neuroleptic agents. Journal of Clinical Psychiatry 2000; 61(Suppl 14)33–42
   PubMed Web of Science ®Google Scholar
• Hayward P, Wong G, Bright JA, Lam D. Stigma and self-esteem in manic depression: An exploratory study. Journal of Affective Disorders 2002; 69(1–3)61–67
   PubMedGoogle Scholar
• Highet NJ, McNair BG, Thompson M, Davenport T. A, Hickie IB. Experience with treatment services for people with bipolar disorder. Medical Journal of Australia 2004; 181(7 Suppl)S47–S51
   Google Scholar
• Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thappa R, et al. A pilot study of barriers to medication adherence in schizophrenia. Journal of Clinical Psychiatry 2004; 65(2)211–216
   PubMed Web of Science ®Google Scholar
• Jenkins JH, Carpenter-Song E. The new paradigm of recovery from schizophrenia: Cultural conundrums of improvement without cure. Culture, Medicine and Psychiatry 2005; 29(4)379–413
   PubMed Web of Science ®Google Scholar
• Jenkins JJ, Strauss ME, Carpenter EA, Miller D, Floersch J, Sajatovic M. Subjective experience of recovery from schizophrenia-related disorders and atypical antipsychotics. International Journal of Social Psychiatry 2005; 51(3)211–217
   PubMed Web of Science ®Google Scholar
• Katschnig H. Schizophrenia and quality of life. Acta Psychiatrica Scandinavica Supplement 2000; 407: 33–37
   Google Scholar
• Lee S, Chiu MY, Tsang A, Chui H, Kleinman A. Stigmatizing experience and structural discrimination associated with the treatment of schizophrenia in Hong Kong. Social Science and Medicine 2006; 62(7)1685–1696
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005; 353(12)1209–1223
   PubMed Web of Science ®Google Scholar
• Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patient's subjective reasons for compliance and non-compliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36: 105–112
   PubMed Web of Science ®Google Scholar
• Moore A, Sellwood W, Stirling J. Compliance and psychological reactance in schizophrenia. British Journal of Clinical Psychology 2000; 39(Pt 3)287–295
   PubMedGoogle Scholar
• Rudge T, Morse K. Did anything change? Caregivers and schizophrenia after medication changes. Journal of Psychiatric and Mental Health Nursing 2004; 11(1)3–11
   PubMedGoogle Scholar
• Sajatovic M, Jenkins JH, Safavi R, West JA, Cassidy KA, Meyer WJ, Calabrese JR. Personal and societal construction of illness among individuals with rapid cycling bipolar disorder: A life trajectory perspective. American Journal of Geriatric Psychiatry, (in press)
   Google Scholar
• Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disorder 2006; 8(3)232–241
   PubMed Web of Science ®Google Scholar
• Simpson GM, Pi EH, Sramek Jr JJ. Management of tardive dyskinesia: Current update. Drugs 1982; 23(5)381–393
   PubMedGoogle Scholar
• Strejilevich S, Garcia Bonetto G. Subjective responses to pharmacological treatments in bipolar patients. Journal of Affective Disorders 2003; 77: 191–192
   PubMedGoogle Scholar
• Struening EL, Perlick DA, Link BG, Hellman F, Herman D, Sirey JA. Stigma as a barrier to recovery: The extent to which caregivers believe most people devalue consumers and their families. Psychiatric Services 2001; 52(12)1633–1638
   PubMed Web of Science ®Google Scholar
• Tsang HW, Tam PK, Chan F, Cheung WM. Sources of burdens on families of individuals with mental illness. International Journal of Rehabilitation Research 2003; 26(2)123–130
   PubMed Web of Science ®Google Scholar
• Van Putten T, May PR, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Archives of General Psychiatry 1981; 38(20)187–190
   PubMedGoogle Scholar
• Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin 1994; 20(2)297–310
   PubMed Web of Science ®Google Scholar
• Yassa R. Functional impairment in tardive dyskinesia: Medical and psychosocial dimensions. Acta Psychiatrica Scandinavica 1989; 80(1)64–67
   PubMed Web of Science ®Google Scholar